IMDX — Insight Molecular Diagnostics Share News
0.000.00%
Last trade - 00:00- $92.61m
- $75.62m
- $4.06m
Brief: Oncocyte Presents Determaio™ Data At Asco 2022 Supporting The Test’S Potential To Expand The Clinical Use Of Immunotherapy
U.S. RESEARCH ROUNDUP-Asgn, Equitable Holdings, Verrica Pharmaceuticals
Brief: OncoCyte Board Has Appointed Andrew Arno As Chairman Of Board
OncoCyte Corp reports results for the quarter ended in March - Earnings Summary
Brief: OncoCyte Reports First Quarter 2022 Financial Results
OncoCyte Corp expected to post a loss of 12 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Digitalbridge Group, Joann, Park Ohio Holdings
U.S. RESEARCH ROUNDUP-DTE Energy, LTC Properties, Visteon
U.S. RESEARCH ROUNDUP- Beauty Health, Mister Car Wash, Nuvei
Brief: Oncocyte Reports Q4 And Full Year 2021 Financial Results
OncoCyte Corp reports results for the quarter ended in December - Earnings Summary
OncoCyte Corp expected to post a loss of 13 cents a share - Earnings Preview
Marketing Agreement With Thermo Fisher Scientific To Expand Access To Precision Oncology
U.S. RESEARCH ROUNDUP-Cerence, Hirequest, Magna International
Brief: OncoCyte’s Determaio Clinical Test Predicts Response To Immunotherapy In Triple Negative Breast Cancer
Brief: Oncocyte Posts Q3 Loss Per Share Of $0.15
OncoCyte Corp reports results for the quarter ended in September - Earnings Summary
Brief: Oncocyte Announces The Clinical Launch Of DetermaIO Immunotherapy Response Prediction Test
Brief: Oncocyte Strengthens Transplant Intellectual Property Portfolio With U.S. Patent